Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/368 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11548224
PMID: | 11548224
LR: | 20041117
CED: | 20010910
DCO: | 20010920
Autoren: | Noack W; Fischer M; Förster KK; Rovati LC; Setnikar I
Titel: | Glucosamine sulfate in osteoarthritis of the knee.
Quelle: | Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society; VOL: 2 (1); p. 51-9 /199403/
PM: | Print
SU: | IM
Sprache: | English
CY: | England
JID: | 9305697
ISSN: | 1063-4584
Institution: | Department of Orthopedics-Evangelisches Waldkrankenhaus, Berlin, Germany.
DT: | Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
Schlagwörter
CT: | ADMINISTRATION, ORAL; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE/*administration & dosage; GLUCOSAMINE/adverse effects; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS/drug therapy; OSTEOARTHRITIS, KNEE/*drug therapy; PAIN/prevention & control; TREATMENT OUTCOME
CTG: | APPLIKATION, ORALE; ERWACHSENER; ALTE MENSCHEN; DOPPELBLINDMETHODE; WEIBLICH; GLUCOSAMIN/*Verabreichung & Dosierung; GLUCOSAMIN/unerwünschte Nebenwirkungen; MENSCH; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; BEWEGUNGSSTÖRUNGEN/Arzneimitteltherapie; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; SCHMERZEN/Verhütung & Bekämpfung; BEHANDLUNGSERGEBNIS
TE: | Glucosamine/3416-24-8
CR: | 3416-24-8
AB: | Glucosamine sulfate is a drug used for the treatment of osteoarthritis (OA), based on its pharmacological and metabolic activities on the cartilage and chondrocytes, complemented by mild anti-inflammatory properties and a favorable pharmacokinetic profile. The aim of this study was to define the activity and safety of glucosamine sulfate on the symptoms of patients with OA, using a multicenter, randomized, placebo-controlled, double-blind, parallel-group study design. The study included 252 outpatients with OA of the knee (Lequesne's criteria), radiological stage between I and III, and Lequesne's severity index of at least 4 points and symptoms for at least 6 months. Patients were treated with either placebo or oral glucosamine sulfate 500 mg t.i.d. for 4 weeks, with weekly, with weekly clinic visits. Responders to treatment were defined as patients with a reduction of at least 3 points in the Lequesne's index with a positive overall assessment by the investigator. The Lequesne's index was 10.6 +/- 0.45 S.E.M. points in both groups at the start of the study. This decreased to 7.45 +/- 0.5 points in the treatment group (average 3.2) and 8.4 +/- 0.4 points in the placebo group (average 2.2) (P < 0.05, Student's t-test). The responder rate in the evaluable patients was 55% with glucosamine (N = 120) vs 38% with placebo (N = 121). These proportions were 52% vs 37% in an intention-to-treat analysis (P = 0.014 and 0.016, respectively; Fisher's Exact Test). The medications were well tolerated throughout the study, with no difference between the glucosamine and placebo treated groups. It is concluded that glucosamine sulfate may be a safe and effective symptomatic Slow Acting Drug for OA.

» Volltext »
» Fenster schließen »